Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026)

Argenx Se's (ARGX) quarterly Total Non-Current Liabilities came in at $40.0 million in Q2 2026, down 99.89% on a YoY basis from $37.9 billion in Q2 2025, and up 2.56% quarter-over-quarter from $39.0 million in Q4 2025.

Analysis

Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Total Non-Current Liabilities for 11 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities fell 99.89% year-over-year to $40.0 million; the trailing twelve-month figure through Jun 2026 stood at $40.0 million (down 99.89% YoY), and the FY2025 full-year result was $39.0 million, down 99.89% from the prior year.
  • Total Non-Current Liabilities grew to $40.0 million in Q2 2026 per ARGX's latest filing, from $39.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $37.9 billion in Q2 2025 and bottomed at $14.4 million in Q2 2022.
  • Historically, Total Non-Current Liabilities has averaged $10.1 billion across 5 years, with a median of $39.0 million in 2025.
  • The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities soared 156212.05% in 2024, then slumped 99.89% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $18.3 billion in 2022, then tumbled by 99.88% to $22.0 million in 2023, then jumped by 156212.05% to $34.3 billion in 2024, then sank by 99.89% to $39.0 million in 2025, then increased by 2.56% to $40.0 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.0 million, $39.0 million, and $37.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 40.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 12.42 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 1.17 Bn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn 739.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Dec 31, 2025 39.00 Mn
Jun 30, 2025 37.94 Bn
Dec 31, 2024 34.32 Bn
Jun 30, 2024 34.68 Mn
Dec 31, 2023 21.96 Mn
Jun 30, 2023 17.95 Mn
Dec 31, 2022 18.29 Bn
Jun 30, 2022 14.42 Mn
Dec 31, 2021 14.81 Bn
Jun 30, 2021 17.05 Mn
Dec 31, 2020 267.56 Bn
Jun 30, 2020 228.32 Mn
Dec 31, 2019 246.43 Mn
Jun 30, 2019 271.20 Mn
Dec 31, 2018 7,989.77
Jun 30, 2018 29,836.11
Dec 31, 2017 1.72 Mn
Jun 30, 2017 1,099.55
Dec 31, 2016 1,087.39